Showing 681-690 of 2293 results for "".
- Short-Term Stress Management Protocol Improves Objective and Self-Reported Measures of Stress and Mood in Patients with MS According to New Researchhttps://practicalneurology.com/news/short-term-stress-management-protocol-improves-objective-and-self-reported-measures-of-stress-and-mood-in-patients-with-ms-according-to-new-research/2470202/Research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) suggests that participating in a program providing short-term psychotherapy in stress management techniques improves mood
- T-Cell Therapy Targeting Epstein-Barr Virus Provided Sustained Disability Improvement for Progressive MS in Phase 1a Clinical Trialhttps://practicalneurology.com/news/t-cell-therapy-targeting-epstein-barr-virus-provided-sustained-disability-improvement-for-progressive-ms-in-phase-1a-clinical-trial/2469377/An Epstein-Barr virus (EBV)-targeting, off-the-shelf allogeneic T-Cell therapy (ATA188; Atara, South San Francisco, CA) was well tolerated and showed signs of efficacy measured as sustained disability improvement (SDI) in participants with progressive multiple sclerosis (PMS). In this Phase 1a 12
- FDA Approves Diroximel Fumarate—A Second Generation Fumarate With Fewer Side Effects—for Treatment of Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-diroximel-fumaratea-second-generation-fumarte-with-fewer-side-effectsfor-treatment-of-multiple-sclerosis/2469063/The Food and Drug Administration has approved diroximel fumarate (Vumerity; Biogen, Cambridge, MA and Alkermes, Dublin, Ireland) for the treatment of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing remitting MS (RRMS), and active secondary progressive MS (SPMS). &n
- Siponimod Approved by FDA for Treatment of Relapsing-Remitting and Secondary-Progressive Multiple Sclerosishttps://practicalneurology.com/news/siponimod-approved-by-fda-for-treatment-of-relapsing-remitting-and-secondary-progressive-multiple-sclerosis/2468792/The first drug to treat 3 phases of multiple sclerosis (MS), secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS), has been approved by the Food and Drug Administration (FDA). Siponimod (Mayzent; Novartis, East Hanover, NJ) is an oral agent a
- In Memoriam: June Halper, MSN, APN-C, FAAN, MSCNhttps://practicalneurology.com/news/in-memoriam-june-halper-msn-apn-c-faan-mscn/2470537/June Halper, MSN, ASPN-C, FAAN, MSCN passed away on July 24, 2024, at age 86. Ms. Halper was a founding member of the Consortium of Multiple Sclerosis Centers (CMSC) and served as the organization’s President from 1995 to 1997 and as its Executive Director/CEO from 1992 until her death. Ms.
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- Nanocrystalline Gold Provides Functional Improvements for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/nanocrystalline-gold-provides-functional-improvements-for-relapsing-multiple-sclerosis/2470004/In the VISIONARY-MS clinical trial (NCT03536559), participants with relapsing multiple sclerosis (MS) and optic neuritis (ON) treated with nanocrystalline gold (CNM-Au8; Clene Inc, Salt Lake City,
- Gastrointestinal Tolerability of Diroximel Fumarate May Shorten Time to Reach Optimal Dosehttps://practicalneurology.com/news/gastrointestinal-tolerability-of-diroximel-fumarate-may-shorten-time-to-reach-optimal-dose/2469719/In the phase 3 EVOLVE-MS-2 study (NCT03093324), individuals with relapsing multiple sclerosis (MS) treated with diroximel fumarate (Vumerity; Biogen, Cambridge, MA) (n=253) had improved gastrointestinal (GI) tolerability compared with
- Study Assesses Biological Age Acceleration in People with Multiple Sclerosishttps://practicalneurology.com/news/study-assesses-biological-age-acceleration-in-people-with-multiple-sclerosis/2470415/Analysis of interim results from a study assessing biological aging in individuals with multiple sclerosis (MS) showed an increase in epigenetic age acceleration (EAA) in a subset of people with secondary progressive MS. The results were presented at the ninth annual Americas Committee for Treatm
- Ketogenic Diet May Reduce Disability and Improve Quality of Life in Multiple Sclerosishttps://practicalneurology.com/news/ketogenic-diet-may-reduce-disability-and-improve-quality-of-life-in-multiple-sclerosis/2469842/A preliminary study found that a ketogenic diet may be safe for people with multiple sclerosis (MS) and reduce fatigue, depression, and disability. Improved quality of life may also occur with a ketogenic diet for people with MS. During the study, 83% of participants adhered to a